首页> 外文期刊>International archives of allergy and immunology >Regulatory T cells control type I food allergy to Beta-lactoglobulin in mice.
【24h】

Regulatory T cells control type I food allergy to Beta-lactoglobulin in mice.

机译:调节性T细胞可控制小鼠对β-乳球蛋白的I型食物过敏。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Regulatory T cells contribute to peripheral immune tolerance, yet their ability to control immediate-type hypersensitivity (ITH) reactions involved in IgE-mediated food allergy is still poorly documented. OBJECTIVES: We investigated in mice whether CD4+CD25+ regulatory T cells could control ITH to beta-lactoglobulin (BLG), a major allergen in cow's milk. METHODS: C3H/HeOuJ mice were sensitized by repeated oral gavage with BLG plus cholera toxin as adjuvant and orally challenged with BLG alone to elicit allergic symptoms. Mice were treated with the anti-CD25 mAb (PC61) before sensitization. Oral sensitization (afferent phase of ITH) was assessed by production of BLG-specific serum antibodies and Th1/Th2-type cytokines by specific CD4+ T cells in mesenteric lymph nodes. ITH was elicited by oral BLG challenge (efferent phase of ITH) and we monitored symptom scores, numbers and function of intestinal mast cells and serum level of the mucosal mast cell protease mMCP-1. RESULTS: Upon oral BLG challenge, orally sensitized mice developed only mild clinical signs. Anti-CD25 mAb-treated mice exhibited enhancement of both BLG-specific CD4+ T cell priming with IL-4, IL-5, IL-13 and IFN-gamma production and total IgE, and BLG-specific IgE, IgG1 and IgG2a in serum. Anti-CD25 mAb treatment caused more severe symptoms upon BLG challenge, which correlated with enhanced serum levels of the mucosal mast cell protease mMCP-1. CONCLUSIONS: These data document that constitutive CD4+CD25+ regulatory T cells alleviate clinical signs of ITH to dietary BLG by modulating the priming of BLG-specific T and B cell responses during oral sensitization and enhancing mast cell degranulation.
机译:背景:调节性T细胞有助于外周免疫耐受,但其控制参与IgE介导的食物过敏的速发型超敏反应(ITH)反应的能力仍知之甚少。目的:我们在小鼠中研究了CD4 + CD25 +调节性T细胞是否可以将ITH控制到牛奶中的主要过敏原β-乳球蛋白(BLG)。方法:以BLG加霍乱毒素为佐剂反复口服管饲法对C3H / HeOuJ小鼠致敏,单独用BLG口服激发以引起过敏症状。在致敏之前,用抗CD25 mAb(PC61)处理小鼠。通过肠系膜淋巴结中特定CD4 + T细胞产生BLG特异性血清抗体和Th1 / Th2型细胞因子来评估口服致敏性(ITH的激进期)。口服BLG激发(ITH的有效期)诱发了ITH,我们监测了症状评分,肠道肥大细胞的数量和功能以及黏膜肥大细胞蛋白酶mMCP-1的血清水平。结果:口服BLG攻击后,口服致敏小鼠仅出现轻度临床症状。抗CD25 mAb治疗的小鼠在血清中表现出IL-4,IL-5,IL-13和IFN-γ产生以及总IgE以及BLG特异性IgE,IgG1和IgG2a增强BLG特异性CD4 + T细胞致敏性。抗CD25 mAb治疗在BLG攻击后引起更严重的症状,这与粘膜肥大细胞蛋白酶mMCP-1的血清水平升高有关。结论:这些数据证明,组成型CD4 + CD25 +调节性T细胞通过调节口腔致敏过程中BLG特异性T和B细胞应答的启动和增强肥大细胞脱粒,减轻了ITH对饮食BLG的临床症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号